Camurus AB
Drugmaker with rare disease work · based in Lund, Sweden · ticker CAMX · camurus.com
Camurus AB works on Acromegaly and Neuroendocrine Tumors, 2 of the rare diseases we track. It has 2 active clinical trials, and 1 is looking for volunteers now.
Camurus is a Swedish drug company based in Lund that makes long-acting injectable medicines, and its marketed products treat opioid dependence. Its CAM2029, a monthly octreotide injection under the skin that patients give with a pen, is approved for acromegaly in the EU and UK as Oczyesa and is under FDA review in the US as Oclaiz, with a decision due December 18, 2026.
Camurus AB pipeline
Each row lists the diseases Camurus AB is studying at that stage, from the ones closest to approval down to the earliest work.
Acromegaly recruiting
Camurus AB clinical trials
These are Camurus AB trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.
1 trial looking for volunteers now
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
Tests Octreotide subcutaneous depot
For Acromegaly
1 trial underway, not taking new volunteers
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Tests CAM2029, Octreotide LAR, Lanreotide ATG
For Gastro-enteropancreatic Neuroendocrine Tumor
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Camurus AB. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Acromegaly. Turn any of these off from the link in every email.
More about Camurus AB
Camurus is also testing CAM2029 in neuroendocrine tumors and polycystic liver disease.
Within its broader pharmaceutical portfolio, Camurus AB has active clinical trial programs and drug development efforts across 2 rare diseases, including Acromegaly, Neuroendocrine Tumors. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows active and recruiting rare disease studies sponsored by Camurus AB, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites.
The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Keep reading about Camurus AB
Camurus AB is headquartered in Lund, Sweden, publicly traded under the ticker symbol CAMX. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Where Camurus AB trials take place
The trials above run at 93 study sites in 13 countries. Tap a country to see its states, cities and hospitals.
Rare diseases Camurus AB works on
Each disease page lists every open trial, not only Camurus AB's, plus approved treatments.
Acromegaly is a rare hormonal disorder caused by excessive growth hormone production, typically from a pituitary adenoma, resulting in abnormal growth of hands, feet, and facial features.
How common: About 50 to 70 people per million, according to NORD, with 3 to 11 new cases per million people each year
Neuroendocrine tumors (NETs) grow from hormone-making cells, most often in the small intestine, pancreas, rectum or lungs.
How common: About 244,000 people in the US were living with a neuroendocrine neoplasm, the wider group that includes NETs, in 2021, with about 8.5 new diagnoses per 100,000 people a year (Dasari et al., JAMA Network Open 2025); an earlier estimate for NETs alone was about 171,000 in 2014 (JAMA Oncology 2017)
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Camurus AB's own site is camurus.com, and our help paying for treatment page lists drugmaker programs and charity funds.
- Acromegaly Community Inc.Acromegaly
- National Organization for Rare Disorders (NORD)Acromegaly
- National Cancer Institute - Gastrointestinal Carcinoid Tumors Treatment (PDQ), Patient VersionNeuroendocrine Tumors
- National Cancer Institute - Pancreatic Neuroendocrine Tumors Treatment (PDQ), Patient VersionNeuroendocrine Tumors